The new year has arrived, and none to soon for many in the biotech industry. To mark the changing of the calendar year, we asked several industry gurus to gaze into their crystal ball for a glimpse of what may come to pass in the year ahead, and beyond.Based on their prognostications, pharma continues to have its work cut out to not only soften the blow from looming patent expirations, but perhaps more importantly, to survive in what E&Y’s Glen Giovannetti calls the emerging health outcomes ecosystem.
To read the full, original article click on this link: 2011: Troublesome transition year for pharma-biotech players « partneringNEWS
